View DividendHyper 경영진경영진 기준 점검 0/4현재 CEO에 대한 정보가 충분하지 않습니다.핵심 정보 최고경영자n/a총 보수CEO 급여 비율n/aCEO 재임 기간no dataCEO 지분 보유율n/a경영진 평균 재임 기간데이터 없음이사회 평균 재임 기간데이터 없음최근 경영진 업데이트공지 • Mar 17Hyper Corporation Inc., Annual General Meeting, Mar 31, 2026Hyper Corporation Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 637, eonju-ro, gangnam-gu, seoul South KoreaBoard Change • Jun 26Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 1 independent director (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공지 • Mar 18Hyper Corporation Inc., Annual General Meeting, Mar 31, 2025Hyper Corporation Inc., Annual General Meeting, Mar 31, 2025, at 08:00 Tokyo Standard Time. Location: conference room, 117, gwacheon-daero 12-gil, gyeonggi-do, gwacheon South KoreaBoard Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 1 independent director (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 1 independent director (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.모든 업데이트 보기Recent updatesNew Risk • Apr 03New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (31% accrual ratio). Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩43.1b market cap, or US$28.6m).New Risk • Mar 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 64% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩43.2b market cap, or US$28.7m).공지 • Mar 17Hyper Corporation Inc., Annual General Meeting, Mar 31, 2026Hyper Corporation Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 637, eonju-ro, gangnam-gu, seoul South Korea공지 • Feb 27Hyper Corporation Inc. has completed a Follow-on Equity Offering in the amount of KRW 14.999999 billion.Hyper Corporation Inc. has completed a Follow-on Equity Offering in the amount of KRW 14.999999 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 8,556,759 Price\Range: KRW 1753 Transaction Features: Subsequent Direct Listing공지 • Dec 31Hyper Corporation Inc. announced that it has received KRW 34.999990179 billion in funding from UTXO Management GP, LLC, Fundpartner Solutions (Europe) SA, Woori Technology Investment Co., Ltd, Fanatic Strategic Holdings Pte. Ltd., Walkers Corporate Limited, Investment Arm, Kingsway Capital Partners LimitedOn December 30, 2025, Hyper Corporation Inc. closed the transaction.분석 기사 • Dec 01Is Hyper (KOSDAQ:065650) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...New Risk • Nov 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 36% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩41.0b market cap, or US$28.1m).공지 • Sep 17Bestand Korea agreed to acquire 89.32% stake in AI Mindbot Equity from Hyper Corporation Inc. (KOSDAQ:A065650) for KRW 8.5 billion.Bestand Korea agreed to acquire 89.32% stake in AI Mindbot Equity from Hyper Corporation Inc. (KOSDAQ:A065650) for KRW 8.5 billion on September 15, 2025. As part of the acquisition, Bestand Korea will acquire 0.021 shares AI Mindbot Equity. The consideration of KRW 8.5 billion will be paid in cash, out of which approximately KRW 850 million is paid as deposit on September 15, 2025 and the remaining KRW 7.6 billion will be paid upon completion of the acquisition. The transaction will be financed through Cash on hand and money borrowing. The expected completion of the transaction is November 7, 2025.New Risk • Aug 30New minor risk - Financial data availabilityLess than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (27% average weekly change). Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (₩58.4b market cap, or US$42.1m).공지 • Aug 08An undisclosed buyer agreed to acquire 19.49% stake in Makeus Co.,Ltd. from Hyper Corporation Inc. (KOSDAQ:A065650) for KRW 2.8 billion.An undisclosed buyer agreed to acquire 19.49% stake in Makeus Co.,Ltd. from Hyper Corporation Inc. (KOSDAQ:A065650) for KRW 2.8 billion on August 7, 2025. A cash consideration of KRW 2.8 billion will be paid by the buyer. As part of consideration, KRW 2.8 billion is paid towards common equity of Makeus Co.,Ltd. The expected completion of the transaction is December 31, 2025.분석 기사 • Jun 26We Think Hyper (KOSDAQ:065650) Has A Fair Chunk Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Board Change • Jun 26Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 1 independent director (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공지 • Mar 18Hyper Corporation Inc., Annual General Meeting, Mar 31, 2025Hyper Corporation Inc., Annual General Meeting, Mar 31, 2025, at 08:00 Tokyo Standard Time. Location: conference room, 117, gwacheon-daero 12-gil, gyeonggi-do, gwacheon South KoreaNew Risk • Feb 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2020 fiscal period end). Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩73.2b market cap, or US$50.3m).공지 • Jun 01+ 2 more updatesMedifron DBT Co., Ltd. (KOSDAQ:A065650) completed the acquisition of 19.49% stake in Makeus Co.,Ltd. from FSN Co., Ltd. (KOSDAQ:A214270).Medifron DBT Co., Ltd. (KOSDAQ:A065650) agreed to acquire 19.49% stake in Makeus Co.,Ltd. from FSN Co., Ltd. (KOSDAQ:A214270) for KRW 7.9 billion on April 5, 2024. As per the transaction, Medifron DBT Co., Ltd. will acquire 4,963 shares of Makeus Co.,Ltd. The transaction will be financed from cash in hand. As of December 2023, Makeus Co.,Ltd. generated total assets of KRW 10.2 billion, total debt of KRW 4.4 billion, total capital KRW 5.8 billion and net loss KRW 403.4 million. Medifron DBT Co., Ltd. (KOSDAQ:A065650) completed the acquisition of 19.49% stake in Makeus Co.,Ltd. from FSN Co., Ltd. (KOSDAQ:A214270) on May 30, 2024.New Risk • May 10New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 78% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2020 fiscal period end). Shareholders have been substantially diluted in the past year (78% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩126.6b market cap, or US$92.7m).공지 • Apr 27Medifron DBT Co., Ltd. announced that it has received KRW 20.999999826 billion in funding from FSN Co., Ltd.On April 26, 2024, Medifron DBT Co., Ltd. closed the transaction.공지 • Feb 17Medifron DBT Co., Ltd. announced that it expects to receive KRW 41.999999652 billion in fundingMedifron DBT Co., Ltd. announces private placement of 41,420,118 shares at an issue price of KRW 1,014 for a gross proceeds of KRW 41,999,999,652 on February 15, 2024. The transaction is expected to close on April 30, 2024. The transaction has been approved by the board of the company.공지 • Feb 16Medifron DBT Co., Ltd. announced that it expects to receive KRW 20.999999826 billion in funding from FSN Co., Ltd.Medifron DBT Co., Ltd. announced a private placement of 20,710,059 common shares at a price of KRW 1,014 per share for the gross proceeds of KRW 20,999,999,826 on February 15, 2024. The transaction will include participation from new investor FSN Co., Ltd. The transaction has ben approved by the shareholders of the company is expected to close on April 26, 2024. The shares are restricted to a hold period of 1 year.New Risk • Feb 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2020 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Shareholders have been diluted in the past year (10.0% increase in shares outstanding). Market cap is less than US$100m (₩75.0b market cap, or US$56.4m).New Risk • Jul 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2020 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Shareholders have been diluted in the past year (7.9% increase in shares outstanding). Market cap is less than US$100m (₩85.5b market cap, or US$66.3m).공지 • Dec 15Medifron DBT Co., Ltd. announced that it has received KRW 4.0000092 billion in funding from T Scientific Co.,LtdOn December 14, 2022, Medifron DBT Co., Ltd. closed the transaction. The company issued 3,427,600 shares in the transaction.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 1 independent director (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공지 • Aug 26Medifron DBT Co., Ltd. announced that it has received KRW 3 billion in fundingOn August 24, 2022, Medifron DBT Co., Ltd. closed the transaction.공지 • Aug 24Medifron DBT Co., Ltd. announced that it expects to receive KRW 3 billion in fundingMedifron DBT Co., Ltd. announced a private placement of series 12 unregistered coupon unguaranteed private convertible bond for gross proceeds of KRW 3,000,000,000 on August 22, 2022. The bonds carry 0% coupon rate, 0% yield to maturity, and will mature on August 24, 2027. The bonds are 100% convertible into 1,784,651 common shares of the company representing 3.93% stake, at a fixed conversion price of KRW 1,681 per share from August 24, 2023 till July 24, 2027. The subscription and payment date for the bonds is August 24, 2022. The transaction has been approved by the board of directors of the company. The bonds will be subject to a hold period of one year.공지 • Jun 23+ 2 more updatesMedifron DBT Co., Ltd. announced that it expects to receive KRW 5 billion in funding from Shinhan Financial Investment Co., Ltd., Mirae Asset Securities Co. Ltd., NH Investment & Securities Co., Ltd., KB Securities Co., Ltd.Medifron DBT Co., Ltd. announced a private placement of series 11 unregistered coupon non-guaranteed private convertible bond for gross proceeds of KRW 5,000,000,000 on June 22, 2022. The transaction will include participation from new investors Shinhan Financial Investment Co., Ltd. for KRW 1,500,000,000, Mirae Asset Securities Co. Ltd. for KRW 2,000,000,000,Pita KOSDAQ Venture General Private Equity Trust No.2, EIP ESG KOSDAQ Venture Specialized Investors General Private Equity Trust No. 1, funds managed by NH Investment & Securities Co., Ltd. for KRW 1,000,000,000, KY KOSDAQ Venture Specialized Investment Criminal Equity Trust No. 3 , fund managed by KB Securities Co., Ltd for KRW 500,000,000. The bonds carry 0% coupon rate, 0% yield to maturity, and will mature on June 30, 2027. The bonds are 100% convertible into 2,797,985 common shares of the company representing 6.42% stake, at a fixed conversion price of KRW 1,787 per share from June 30, 2023 till May 30, 2027. The subscription and payment date for the bonds is June 30, 2022. The transaction has been approved by the board of directors of the company. The bonds will be subject to a hold period of one year.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 1 independent director (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.분석 기사 • Mar 15Should Medifron DBT (KOSDAQ:065650) Be Disappointed With Their 48% Profit?While Medifron DBT Co., Ltd. ( KOSDAQ:065650 ) shareholders are probably generally happy, the stock hasn't had...Is New 90 Day High Low • Mar 08New 90-day low: ₩3,480The company is down 17% from its price of ₩4,200 on 08 December 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 19% over the same period.공지 • Feb 06Medifron DBT Co., Ltd. announced that it has received KRW 14.99999874 billion in funding from T Scientific Co., Ltd.On February 5, 2021, Medifron DBT Co., Ltd. (KOSDAQ:A065650) closed the transaction.Is New 90 Day High Low • Jan 28New 90-day low: ₩3,620The company is down 10.0% from its price of ₩4,030 on 30 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 56% over the same period.Is New 90 Day High Low • Dec 18New 90-day low: ₩3,985The company is down 20% from its price of ₩5,010 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 14% over the same period.공지 • Dec 02Medifron DBT Co., Ltd. announced that it expects to receive KRW 8 billion in fundingMedifron DBT Co., Ltd. (KOSDAQ:A065650) announced a private placement of series 9 domestic unregistered non-guaranteed private convertible bond for gross proceeds of KRW 8,000,000,000 on November 30, 2020. The transaction will include participation from new investor J&Giant Spice Private Equity Partnership. The bonds carry 0% coupon rate, 0% yield to maturity, will mature on December 4, 2023, and are 100% convertible into 1,777,777 common shares of the company representing 4.78% stake, at a fixed conversion price of KRW 4,500 per share from December 4, 2021 till November 4, 2024. The payment date for the bonds is December 4, 2020. The transaction has been approved by the board of directors of the company.분석 기사 • Nov 29Despite Lacking Profits Medifron DBT (KOSDAQ:065650) Seems To Be On Top Of Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is New 90 Day High Low • Oct 19New 90-day low: ₩4,460The company is down 7.0% from its price of ₩4,810 on 21 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 6.0% over the same period.공지 • Sep 03Medifron DBT Co., Ltd. announced that it has received KRW 20 billion in funding from T.S. Investment CorporationOn September 1, 2020, Medifron DBT Co., Ltd. (KOSDAQ:A065650) closed the transaction.공지 • Aug 26Medifron DBT Co., Ltd. announced that it expects to receive KRW 20 billion in funding from T.S. Investment CorporationMedifron DBT Co., Ltd. (KOSDAQ:A065650) announced a private placement of series 8 domestic unregistered non-guaranteed private convertible bond for gross proceeds of KRW 20,000,000,000 on August 25, 2020. The transaction will include participation from new investor T.S. 2018-12 M&A Investment Fund, a fund managed by returning investor T.S. Investment Corporation (KOSDAQ:A246690). The bonds carry 0% coupon rate, 0% yield to maturity, will mature on September 01, 2025, and are 100% convertible into 3,998,400 common shares of the company representing 10.75% stake, at a fixed conversion price of KRW 5,002 per share from September 01, 2021 till August 01, 2025. The payment date for the bonds is September 01, 2020. The transaction has been approved by the board of directors of the company.CEOHyper에는 CEO가 없거나 해당 데이터가 없습니다.View Ownership기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/07 04:21종가2026/04/30 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Hyper Corporation Inc.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관NaYeon KimMirae Asset Securities Co., Ltd.
공지 • Mar 17Hyper Corporation Inc., Annual General Meeting, Mar 31, 2026Hyper Corporation Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 637, eonju-ro, gangnam-gu, seoul South Korea
Board Change • Jun 26Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 1 independent director (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공지 • Mar 18Hyper Corporation Inc., Annual General Meeting, Mar 31, 2025Hyper Corporation Inc., Annual General Meeting, Mar 31, 2025, at 08:00 Tokyo Standard Time. Location: conference room, 117, gwacheon-daero 12-gil, gyeonggi-do, gwacheon South Korea
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 1 independent director (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 1 independent director (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
New Risk • Apr 03New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (31% accrual ratio). Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩43.1b market cap, or US$28.6m).
New Risk • Mar 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 64% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩43.2b market cap, or US$28.7m).
공지 • Mar 17Hyper Corporation Inc., Annual General Meeting, Mar 31, 2026Hyper Corporation Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 637, eonju-ro, gangnam-gu, seoul South Korea
공지 • Feb 27Hyper Corporation Inc. has completed a Follow-on Equity Offering in the amount of KRW 14.999999 billion.Hyper Corporation Inc. has completed a Follow-on Equity Offering in the amount of KRW 14.999999 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 8,556,759 Price\Range: KRW 1753 Transaction Features: Subsequent Direct Listing
공지 • Dec 31Hyper Corporation Inc. announced that it has received KRW 34.999990179 billion in funding from UTXO Management GP, LLC, Fundpartner Solutions (Europe) SA, Woori Technology Investment Co., Ltd, Fanatic Strategic Holdings Pte. Ltd., Walkers Corporate Limited, Investment Arm, Kingsway Capital Partners LimitedOn December 30, 2025, Hyper Corporation Inc. closed the transaction.
분석 기사 • Dec 01Is Hyper (KOSDAQ:065650) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
New Risk • Nov 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 36% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩41.0b market cap, or US$28.1m).
공지 • Sep 17Bestand Korea agreed to acquire 89.32% stake in AI Mindbot Equity from Hyper Corporation Inc. (KOSDAQ:A065650) for KRW 8.5 billion.Bestand Korea agreed to acquire 89.32% stake in AI Mindbot Equity from Hyper Corporation Inc. (KOSDAQ:A065650) for KRW 8.5 billion on September 15, 2025. As part of the acquisition, Bestand Korea will acquire 0.021 shares AI Mindbot Equity. The consideration of KRW 8.5 billion will be paid in cash, out of which approximately KRW 850 million is paid as deposit on September 15, 2025 and the remaining KRW 7.6 billion will be paid upon completion of the acquisition. The transaction will be financed through Cash on hand and money borrowing. The expected completion of the transaction is November 7, 2025.
New Risk • Aug 30New minor risk - Financial data availabilityLess than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (27% average weekly change). Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (₩58.4b market cap, or US$42.1m).
공지 • Aug 08An undisclosed buyer agreed to acquire 19.49% stake in Makeus Co.,Ltd. from Hyper Corporation Inc. (KOSDAQ:A065650) for KRW 2.8 billion.An undisclosed buyer agreed to acquire 19.49% stake in Makeus Co.,Ltd. from Hyper Corporation Inc. (KOSDAQ:A065650) for KRW 2.8 billion on August 7, 2025. A cash consideration of KRW 2.8 billion will be paid by the buyer. As part of consideration, KRW 2.8 billion is paid towards common equity of Makeus Co.,Ltd. The expected completion of the transaction is December 31, 2025.
분석 기사 • Jun 26We Think Hyper (KOSDAQ:065650) Has A Fair Chunk Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Board Change • Jun 26Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 1 independent director (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공지 • Mar 18Hyper Corporation Inc., Annual General Meeting, Mar 31, 2025Hyper Corporation Inc., Annual General Meeting, Mar 31, 2025, at 08:00 Tokyo Standard Time. Location: conference room, 117, gwacheon-daero 12-gil, gyeonggi-do, gwacheon South Korea
New Risk • Feb 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2020 fiscal period end). Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩73.2b market cap, or US$50.3m).
공지 • Jun 01+ 2 more updatesMedifron DBT Co., Ltd. (KOSDAQ:A065650) completed the acquisition of 19.49% stake in Makeus Co.,Ltd. from FSN Co., Ltd. (KOSDAQ:A214270).Medifron DBT Co., Ltd. (KOSDAQ:A065650) agreed to acquire 19.49% stake in Makeus Co.,Ltd. from FSN Co., Ltd. (KOSDAQ:A214270) for KRW 7.9 billion on April 5, 2024. As per the transaction, Medifron DBT Co., Ltd. will acquire 4,963 shares of Makeus Co.,Ltd. The transaction will be financed from cash in hand. As of December 2023, Makeus Co.,Ltd. generated total assets of KRW 10.2 billion, total debt of KRW 4.4 billion, total capital KRW 5.8 billion and net loss KRW 403.4 million. Medifron DBT Co., Ltd. (KOSDAQ:A065650) completed the acquisition of 19.49% stake in Makeus Co.,Ltd. from FSN Co., Ltd. (KOSDAQ:A214270) on May 30, 2024.
New Risk • May 10New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 78% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2020 fiscal period end). Shareholders have been substantially diluted in the past year (78% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩126.6b market cap, or US$92.7m).
공지 • Apr 27Medifron DBT Co., Ltd. announced that it has received KRW 20.999999826 billion in funding from FSN Co., Ltd.On April 26, 2024, Medifron DBT Co., Ltd. closed the transaction.
공지 • Feb 17Medifron DBT Co., Ltd. announced that it expects to receive KRW 41.999999652 billion in fundingMedifron DBT Co., Ltd. announces private placement of 41,420,118 shares at an issue price of KRW 1,014 for a gross proceeds of KRW 41,999,999,652 on February 15, 2024. The transaction is expected to close on April 30, 2024. The transaction has been approved by the board of the company.
공지 • Feb 16Medifron DBT Co., Ltd. announced that it expects to receive KRW 20.999999826 billion in funding from FSN Co., Ltd.Medifron DBT Co., Ltd. announced a private placement of 20,710,059 common shares at a price of KRW 1,014 per share for the gross proceeds of KRW 20,999,999,826 on February 15, 2024. The transaction will include participation from new investor FSN Co., Ltd. The transaction has ben approved by the shareholders of the company is expected to close on April 26, 2024. The shares are restricted to a hold period of 1 year.
New Risk • Feb 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2020 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Shareholders have been diluted in the past year (10.0% increase in shares outstanding). Market cap is less than US$100m (₩75.0b market cap, or US$56.4m).
New Risk • Jul 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2020 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Shareholders have been diluted in the past year (7.9% increase in shares outstanding). Market cap is less than US$100m (₩85.5b market cap, or US$66.3m).
공지 • Dec 15Medifron DBT Co., Ltd. announced that it has received KRW 4.0000092 billion in funding from T Scientific Co.,LtdOn December 14, 2022, Medifron DBT Co., Ltd. closed the transaction. The company issued 3,427,600 shares in the transaction.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 1 independent director (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공지 • Aug 26Medifron DBT Co., Ltd. announced that it has received KRW 3 billion in fundingOn August 24, 2022, Medifron DBT Co., Ltd. closed the transaction.
공지 • Aug 24Medifron DBT Co., Ltd. announced that it expects to receive KRW 3 billion in fundingMedifron DBT Co., Ltd. announced a private placement of series 12 unregistered coupon unguaranteed private convertible bond for gross proceeds of KRW 3,000,000,000 on August 22, 2022. The bonds carry 0% coupon rate, 0% yield to maturity, and will mature on August 24, 2027. The bonds are 100% convertible into 1,784,651 common shares of the company representing 3.93% stake, at a fixed conversion price of KRW 1,681 per share from August 24, 2023 till July 24, 2027. The subscription and payment date for the bonds is August 24, 2022. The transaction has been approved by the board of directors of the company. The bonds will be subject to a hold period of one year.
공지 • Jun 23+ 2 more updatesMedifron DBT Co., Ltd. announced that it expects to receive KRW 5 billion in funding from Shinhan Financial Investment Co., Ltd., Mirae Asset Securities Co. Ltd., NH Investment & Securities Co., Ltd., KB Securities Co., Ltd.Medifron DBT Co., Ltd. announced a private placement of series 11 unregistered coupon non-guaranteed private convertible bond for gross proceeds of KRW 5,000,000,000 on June 22, 2022. The transaction will include participation from new investors Shinhan Financial Investment Co., Ltd. for KRW 1,500,000,000, Mirae Asset Securities Co. Ltd. for KRW 2,000,000,000,Pita KOSDAQ Venture General Private Equity Trust No.2, EIP ESG KOSDAQ Venture Specialized Investors General Private Equity Trust No. 1, funds managed by NH Investment & Securities Co., Ltd. for KRW 1,000,000,000, KY KOSDAQ Venture Specialized Investment Criminal Equity Trust No. 3 , fund managed by KB Securities Co., Ltd for KRW 500,000,000. The bonds carry 0% coupon rate, 0% yield to maturity, and will mature on June 30, 2027. The bonds are 100% convertible into 2,797,985 common shares of the company representing 6.42% stake, at a fixed conversion price of KRW 1,787 per share from June 30, 2023 till May 30, 2027. The subscription and payment date for the bonds is June 30, 2022. The transaction has been approved by the board of directors of the company. The bonds will be subject to a hold period of one year.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 1 independent director (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
분석 기사 • Mar 15Should Medifron DBT (KOSDAQ:065650) Be Disappointed With Their 48% Profit?While Medifron DBT Co., Ltd. ( KOSDAQ:065650 ) shareholders are probably generally happy, the stock hasn't had...
Is New 90 Day High Low • Mar 08New 90-day low: ₩3,480The company is down 17% from its price of ₩4,200 on 08 December 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 19% over the same period.
공지 • Feb 06Medifron DBT Co., Ltd. announced that it has received KRW 14.99999874 billion in funding from T Scientific Co., Ltd.On February 5, 2021, Medifron DBT Co., Ltd. (KOSDAQ:A065650) closed the transaction.
Is New 90 Day High Low • Jan 28New 90-day low: ₩3,620The company is down 10.0% from its price of ₩4,030 on 30 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 56% over the same period.
Is New 90 Day High Low • Dec 18New 90-day low: ₩3,985The company is down 20% from its price of ₩5,010 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 14% over the same period.
공지 • Dec 02Medifron DBT Co., Ltd. announced that it expects to receive KRW 8 billion in fundingMedifron DBT Co., Ltd. (KOSDAQ:A065650) announced a private placement of series 9 domestic unregistered non-guaranteed private convertible bond for gross proceeds of KRW 8,000,000,000 on November 30, 2020. The transaction will include participation from new investor J&Giant Spice Private Equity Partnership. The bonds carry 0% coupon rate, 0% yield to maturity, will mature on December 4, 2023, and are 100% convertible into 1,777,777 common shares of the company representing 4.78% stake, at a fixed conversion price of KRW 4,500 per share from December 4, 2021 till November 4, 2024. The payment date for the bonds is December 4, 2020. The transaction has been approved by the board of directors of the company.
분석 기사 • Nov 29Despite Lacking Profits Medifron DBT (KOSDAQ:065650) Seems To Be On Top Of Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Is New 90 Day High Low • Oct 19New 90-day low: ₩4,460The company is down 7.0% from its price of ₩4,810 on 21 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 6.0% over the same period.
공지 • Sep 03Medifron DBT Co., Ltd. announced that it has received KRW 20 billion in funding from T.S. Investment CorporationOn September 1, 2020, Medifron DBT Co., Ltd. (KOSDAQ:A065650) closed the transaction.
공지 • Aug 26Medifron DBT Co., Ltd. announced that it expects to receive KRW 20 billion in funding from T.S. Investment CorporationMedifron DBT Co., Ltd. (KOSDAQ:A065650) announced a private placement of series 8 domestic unregistered non-guaranteed private convertible bond for gross proceeds of KRW 20,000,000,000 on August 25, 2020. The transaction will include participation from new investor T.S. 2018-12 M&A Investment Fund, a fund managed by returning investor T.S. Investment Corporation (KOSDAQ:A246690). The bonds carry 0% coupon rate, 0% yield to maturity, will mature on September 01, 2025, and are 100% convertible into 3,998,400 common shares of the company representing 10.75% stake, at a fixed conversion price of KRW 5,002 per share from September 01, 2021 till August 01, 2025. The payment date for the bonds is September 01, 2020. The transaction has been approved by the board of directors of the company.